Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin (BI 1356) in Type 2 Diabetes Patients on Sulfonylurea
NCT00819091Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 1356 with Placebo (2 arms). Primary endpoint: Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18. Started Dec 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00819091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00819091.